This summer, communities throughout the country are experiencing periods of intense heat, and there’s more to come.

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

A new study led by researchers at the University of Rochester Medical Center (URMC) found that early-life exposure to ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic and progressive lung condition that ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.